<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0805257360
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AMLOPHAR 5MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C , Protect from light and moisture
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Amlophar</strong> contains the active substance amlodipine which belongs to a group of medicines called calcium antagonists.</p><p><strong>Amlophar</strong> is used to treat high blood pressure (hypertension) or a certain type of chest pain called angina, a rare form of which is Prinzmetal&rsquo;s or variant angina.</p><p>In patients with high blood pressure this medicine works by relaxing blood vessels, so that blood passes through them more easily. In patients with angina, <strong>Amlophar</strong> works by improving blood supply to the heart muscle which then receives more oxygen and as a result chest pain is prevented. This medicine does not provide immediate relief of chest pain from angina.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Amlophar </strong></p><p>&bull; If you are allergic (hypersensitive) to amlodipine or any of the other ingredients of this medicine listed in section 6: Further Information, or to any other calcium antagonists. This may be itching, reddening of the skin or difficulty in breathing.</p><p>&bull; If you have severe low blood pressure (hypotension).</p><p>&bull; If you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).</p><p>&bull; If you suffer from heart failure after a heart attack.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking <strong>Amlophar</strong>.</p><p>You should inform your doctor if you have or have had any of the following conditions:</p><p>&bull; Recent heart attack</p><p>&bull; Heart failure</p><p>&bull; Severe increase in blood pressure (Hypertensive crisis)</p><p>&bull; Liver disease</p><p>&bull; You are elderly and your dose needs to be increased</p><p><strong>Children and adolescents </strong></p><p>Amlodipine has not been studied in children under the age of 6 years. Amlodipine should only be used for hypertension in children and adolescents from 6 years to 17 years of age (see section 3: How to take <strong>Amlophar</strong>)</p><p>For more information, talk to your doctor.</p><p><strong>Other medicines and Amlophar</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Amlophar</strong> may affect or be affected by other medicines, such as:</p><p>&bull; Ketoconazole, itraconazole (anti-fungal medicines)</p><p>&bull; Ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV)</p><p>&bull; Rifampicin, erythromycin, clarithromycin (antibiotics)</p><p>&bull; Hypericum perforatum (St. John&rsquo;s Wort)</p><p>&bull; Verapamil, diltiazem (heart medicines)</p><p>&bull; Dantrolene (infusion for severe body temperature abnormalities)</p><p>&bull; Tacrolimus sirolimus, temsirolimus, and everolimus (medicines used to alter the way your immune system works)</p><p>&bull; Simvastatin (cholesterol lowering medicine)</p><p>&bull; Cyclosporine (an immunosuppressant)</p><p><strong>Amlophar</strong> may lower your blood pressure even more if you are already taking other medicines to treat your high blood pressure.</p><p><strong>Amlophar with food and drink&nbsp; </strong></p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking <strong>Amlophar</strong>. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of <strong>Amlophar</strong>.&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p><strong><u>Pregnancy </u></strong></p><p>The safety of amlodipine in human pregnancy has not been established. If you think you might be pregnant, or are planning to get pregnant, you must tell your doctor before you take <strong>Amlophar</strong>.</p><p><strong><u>Breast-feeding </u></strong></p><p>Amlodipine has been shown to pass into breast milk in small amounts. If you are breast-feeding or about to start breast-feeding you must tell your doctor before taking <strong>Amlophar</strong>.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines </strong></p><p><strong>Amlophar</strong> may affect your ability to drive or use machines. If the capsules make you feel sick, dizzy or tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended initial dose is <strong>Amlophar</strong> 5mg once daily. The dose can be increased to 10mg once daily.</p><p>This medicine can be used before or after food and drinks. You should take this medicine at the same time each day with a drink of water. Do not take <strong>Amlophar</strong> with grapefruit juice.</p><p><strong>Use in children and adolescents </strong></p><p>For children and adolescents (6-17 years old), the recommended usual starting dose is 2.5mg a day. The maximum recommended dose is 5mg a day. It is important to keep taking the capsules. Do not wait until your capsules are finished before seeing your doctor.</p><p><strong>If you take more Amlophar than you should&nbsp; </strong></p><p>Taking too many capsules may cause your blood pressure to become low or even dangerously low. You may feel dizzy, lightheaded, faint or weak. If blood pressure drop is severe enough shock can occur. Your skin could feel cool and clammy and you could lose consciousness. Seek immediate medical attention if you take too many <strong>Amlophar</strong> capsules.</p><p><strong>If you forget to take Amlophar </strong></p><p>Do not worry. If you forget to take a capsule, leave out that dose completely. Take your next dose at the right time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Amlophar </strong></p><p>Your doctor will advise you how long to take this medicine. Your condition may return if you stop using this medicine before you are advised.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Visit your doctor <strong>immediately </strong>if you experience any of the following side effects after taking this medicine.</p><p>&bull; Sudden wheeziness, chest pain, shortness of breath or difficulty in breathing</p><p>&bull; Swelling of eyelids, face or lips</p><p>&bull; Swelling of the tongue and throat which causes great difficulty breathing</p><p>&bull; Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, toxic epidermal necrolysis) or other allergic reactions</p><p>&bull; Heart attack, abnormal heart beat</p><p>&bull; Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell</p><p>The following <strong>very common side effect </strong>has been reported. If this causes you problems or if it <strong>lasts for more than one week</strong>, you should <strong>contact your doctor. </strong></p><p><strong>Very common: may affect more than 1 in 10 people </strong></p><p>&bull; Oedema (Fluid retention)</p><p>The following <strong>common side effects </strong>have been reported. If any of these cause you problems or if they <strong>last for more than one week</strong>, you should <strong>contact your doctor.</strong></p><p><strong>Common: may affect up to 1 in 10 people </strong></p><p>&bull; Headache, dizziness, sleepiness (especially at the beginning of treatment)</p><p>&bull; Palpitations (awareness of your heart beat), flushing</p><p>&bull; Abdominal pain, feeling sick (nausea)</p><p>&bull; Altered bowel habits, diarrhoea, constipation, indigestion,</p><p>&bull; Tiredness, weakness</p><p>&bull; Visual disturbances, double vision</p><p>&bull; Muscle cramps</p><p>&bull; Ankle swelling &nbsp;</p><p>Other side effects that have been reported include the following list. If any of these get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p><strong>Uncommon: may affect up to 1 in 100 people </strong></p><p>&bull; Mood changes, anxiety, depression, sleeplessness</p><p>&bull; Trembling, taste abnormalities, fainting</p><p>&bull; Numbness or tingling sensation in your limbs, loss of pain sensation</p><p>&bull; Ringing in the ears</p><p>&bull; Low blood pressure</p><p>&bull; Sneezing/running nose caused by inflammation of the lining of the nose (rhinitis)</p><p>&bull; Cough</p><p>&bull; Dry mouth, vomiting (being sick)</p><p>&bull; Hair loss, increased sweating, itchy skin, red patches on skin, skin discolouration</p><p>&bull; Disorder in passing urine, increased need to urinate at night, increased number of times of passing urine</p><p>&bull; Inability to obtain an erection, discomfort or enlargement of the breasts in men</p><p>&bull; Pain, feeling unwell</p><p>&bull; Joint or muscle pain, back pain</p><p>&bull; Weight increase or decrease</p><p><strong>Rare: may affect up to 1 in 1,000 people </strong></p><p>&bull; Confusion</p><p><strong>Very rare: may affect up to 1 in 10,000 people </strong></p><p>&bull; Decreased numbers of white blood cells, decrease in blood platelets which may result in unusual bruising or easy bleeding</p><p>&bull; Excess sugar in blood (hyperglycaemia)</p><p>&bull; A disorder of the nerves which can cause muscular weakness, tingling or numbness</p><p>&bull; Swelling of the gums</p><p>&bull; Abdominal bloating (gastritis)</p><p>&bull; Abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests</p><p>&bull; Increased muscle tension</p><p>&bull; Inflammation of blood vessels, often with skin rash</p><p>&bull; Sensitivity to light</p><p>&bull; Disorders combining rigidity, tremor, and/or movement disorders</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&bull; Trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk</p><p><strong>If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</strong></p><p><strong>You can also report side effects directly via:</strong></p><p>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>- SFDA Call Centre:</strong> 19999</p><p><strong>- E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>- Website:</strong> https://ade.sfda.gov.sa/</p><p>&bull;&nbsp; <strong>Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>Please contact the relevant competent authority.</strong></p><p>By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.</p><p>- Do not take <strong>Amlophar</strong> after the expiry date which is stated on the carton and on the blister.</p><p>- Store below 30&deg;C, in a dry place.</p><p>- Do not take <strong>Amlophar </strong>if you notice any visible sign of deterioration.</p><p>- Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Amlophar contains</strong></p><p>The active ingredient is Amlodipine. Each capsule contains 5mg of Amlodipine as Amlodipine Besylate.</p><p>The other ingredients: Microcrystalline cellulose, dibasic calcium phosphate, Sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, gelatin, quinoline yellow E104 and titanium dioxide E171.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Amlophar Capsules are available in packs of 30 capsules (2 blisters of 15 capsules each).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                27/05/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتو<strong>ي أملوفار </strong>على أملوديبين كمادة فعالة والتي تنتمي إلى مجموعة من الأدوية تعرف باسم غالقات قنوات الكالسيوم.</p><p dir="RTL">يستخدم <strong>أملوفار</strong> لعلاج ارتفاع ضغط الدم أو نوع معين من ألم الصدر يعرف باسم الذبحة الصدرية، و هو نوع نادر يعرف باسم برنزميتال أو الذبحة المخالفة للمعتاد.</p><p dir="RTL">يعمل هذا الدواء في المرضى الذين يعانون من ارتفاع ضغط الدم عن طريق إرتخاء الأوعية الدموية، مما يسهل تدفق الدم في الأوعية الدموية. يعمل<strong> أملوفار</strong> لدى المرضى الذين يعانون من الذبحة الصدرية عن طريق تحسين وصول الدم المغذي لعضلة القلب والتي بعد ذلك سوف تزود بالكثير من الأكسجين وكنتيجة لذلك سوف يتم الحد من ألم الصدر. لا يخفف هذا الدواء الألم الناتج عن الذبحة الصدرية على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عليك عدم تناول أملوفار في الحالات التالية:</strong></p><p dir="RTL">&nbsp;&nbsp; إذا كنت تعاني من حساسية (فرط الحساسية) تجاه أملوديبين أو أياً من المكونات الأخرى في هذا الدواء المذكورة في البند رقم 6، أو أياً من غالقات قنوات الكالسيوم الأخرى. قد تتضمن أعراض الحساسية على حكة، احمرار الجلد أو صعوبة في التنفس.</p><p dir="RTL">&nbsp;&nbsp; إذا كنت تعاني من انخفاض في ضغط الدم.</p><p dir="RTL">&nbsp;&nbsp; إذا كنت تعاني من ضيق في الصمام الأورطي (ضيق الصمام الأبهري) أو صدمة قلبية (هي حالة حيث يكون القلب غير قادراً على تزويد الكمية الكافية من الدم للجسم )</p><p dir="RTL">&nbsp;&nbsp; إذا كنت تعاني من قصور في القلب بعد &nbsp;حدوث الأزمة القلبية.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يرجى منك التحدث مع طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل<strong> </strong>تناول<strong> أملوفار.</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تعاني أو عانيت من أي الحالات الآتية:</p><p dir="RTL">&nbsp;&nbsp; أزمة قلبية</p><p dir="RTL">&nbsp;&nbsp; قصور في القلب</p><p dir="RTL">&nbsp;&nbsp; ارتفاع شديد في ضغط الدم (أزمة فرط ضغط الدم)</p><p dir="RTL">&nbsp;&nbsp; مرض في الكبد</p><p dir="RTL">&nbsp;&nbsp; إذا كنت من فئة كبار السن وتحتاج إلى زيادة مقدارالجرعة من الدواء</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة أملوديبين على الأطفال بعمر أقل من 6 سنوات. يجب فقط إعطاءأملوديبين في الأطفال والمراهقين بعمر يتراوح بين 6 سنوات إلى 17 سنة &nbsp;الذين يعانون من ارتفاع في ضغط الدم (انظر قسم 3: كيفية تناول <strong>أملوفار</strong>).</p><p dir="RTL">للحصول على معلومات إضافية، يرجى منك التحدث إلى طبيبك المعالج.</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن مع أملوفار</strong><strong> </strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;يرجى إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية.</p><p dir="RTL">&nbsp;&nbsp;قد يؤثر <strong>أملوفار</strong> على آلية عمل الأدوية الأخرى أو قد تؤثر بعض الأدوية الأخرى على آلية عمل <strong>أملوفار</strong>، على سبيل المثال:</p><p dir="RTL">&nbsp; &nbsp;كيتوكونازول، اتراكونازول (الأدوية المضادة للفطريات)</p><p dir="RTL">&nbsp;&nbsp; ريتونافير، اندينافير، نلفينافير (تعرف باسم مثبطات الأنزيم البروتيني تستخدم لعلاج فيروس نقص المناعة البشرية المكتسبة)</p><p dir="RTL">&nbsp;&nbsp; ريفامبسين، اريثرومايسن، كلاريثرومايسين (مضادات حيوية)</p><p dir="RTL">&nbsp;&nbsp; العرن المثقوب أو عشبة العرن (نبتة سانت جون)</p><p dir="RTL">&nbsp;&nbsp; فيراباميل، دلتيازيم (أدوية&nbsp; لعلاج مشاكل القلب)</p><p dir="RTL">&nbsp;&nbsp; دانترولين ( يستخدم عن طريق التسريب لعلاج الاضطرابات الشديدة في درجة حرارة الجسم)</p><p dir="RTL">&nbsp;&nbsp; تاكروليمس سيروليمس، تمسيروليمس وإيفيروليمس )أدوية تعمل على تغير آلية عمل الجهاز المناعي لديك(</p><p dir="RTL">&nbsp;&nbsp; سيمفاستاتين (أدوية تستخدم لتقليل مستوى الكوليسترول في الدم)</p><p dir="RTL">&nbsp;&nbsp; سيكلوسبورين (دواء يستخدم لتثبيط المناعة)</p><p dir="RTL">قد يقلل <strong>أملوفار</strong> ضغط الدم المرتفع لديك بصورة أكبر لو كنت تستعمل بالفعل دواء آخر يعمل على خفض ضغط الدم المرتفع.</p><p dir="RTL"><strong>أملوفار</strong> <strong>مع الطعام والشراب</strong></p><p dir="RTL">يجب عدم شرب عصير الجريب فروت وتناول الجريب فروت لدى المرضى الذين يتم علاجهم بكبسولات <strong>أملوفار</strong>. ذلك لأن جريب فروت وعصير جريب فروت من الممكن أن يؤدي إلى زيادة نسبة المادة الفعالة أملوديبين في الدم، حيث قد يؤدي إلى زيادة غير متوقعة في تأثير <strong>أملوفار</strong> لخفض ضغط الدم.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong><u>الحمل </u></strong></p><p dir="RTL">&nbsp;لم تتم الدراسة على مدى سلامة أملوديبين على الحوامل. يجب عليك إخبار طبيبك المعالج قبل تناول <strong>أملوفار</strong> إذا كنت تعتقدين أنك حاملاً، أو تخططين كي تصبحين حاملاً<strong>.</strong></p><p dir="RTL"><strong><u>الرضاعة الطبيعية</u></strong></p><p dir="RTL">لقد لوحظ أن أملوديبين يفرز بكميات ضئيلة في حليب الثدي. يجب عليك إخبار طبيبك المعالج قبل تناول <strong>أملوفار</strong> إذا كنت ترضعين طفلك رضاعة طبيعية أو على وشك البدء بالرضاعة الطبيعية.</p><p dir="RTL">يرجى منك استشارة الطبيب المعالج أو الصيدلي الذي تتعاملين معه للحصول على النصيحة قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يؤثر<strong> أملوفار</strong>على قدرتك على القيادة أو استخدام الآلات. إذا كان تناول الكبسولات يجعلك تشعر بالإعياء، الدوخة، أو التعب، أو قد يسبب الصداع، ، فيجب عليك عدم القيادة أو استخدام الآلات وتواصل مع طبيبك المعالج على الفور.<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك دائماً تناول هذا الدواء بدقة وفقاً لتعليمات طبيبك المعالج أو الصيدلي الذي تتعامل معه. كما يجب عليك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه مالم تكن متاكداً من كيفية تناول هذا الدواء.</p><p dir="RTL">يبلغ مقدارالجرعة الإبتدائية الموصى بها من<strong> أملوفار</strong> 5 ملغم مرة واحدة يومياً. من الممكن زيادة مقدار الجرعة من حتى تصل إلى 10 ملغم &nbsp;مرة واحدة يومياً.</p><p dir="RTL">يمكن أن يستخدم هذا الدواء قبل أو بعد وجبات الطعام أو الشراب. يجب أن تتناول هذا الدواء كل يوم في نفس الوقت مع كوباً من الماء. &nbsp;يجب عدم تناول <strong>أملوفار</strong> بالتزامن مع عصير الجريب فروت.</p><p dir="RTL"><strong>الاستخدام من قبل المراهقين والأطفال</strong></p><p dir="RTL">يبلغ مقدار الجرعة الإبتدائية الإعتيادية الموصى بها للأطفال والمراهقين (6-17 سنة)، 2,5 ملغم يومياً. يبلغ مقدار الجرعة القصوى الموصى بها 5 ملغم يومياً.</p><p dir="RTL">من الضروري المداومة على تناول الكبسولات. يجب عدم الانتظار حتى تنتهي كمية الدواء الموصوفة لك قبل استشارة طبيبك المعالج.</p><p dir="RTL"><strong>إذا تناولت أملوفار أكثر مما يجب</strong></p><p dir="RTL">إن تناول العديد من الكبسولات قد يسبب هبوط أو هبوط شديد في ضغط الدم وقد يكون خطيراً.</p><p dir="RTL">قد تشعر بالدوخة، دوار خفيف، على وشك الإغماء أو الشعور بالوهن. إذا انخفض ضغط الدم بصورة كبيرة قد يؤدي ذلك إلى حدوث صدمة. قد تشعر بالبرودة والرطوبة في الجلد وقد تؤدي إلى فقدان الوعي. إذا تناولت العديد من كبسولات <strong>أملوفار</strong> يجب عليك طلب المشورة الطبية على الفور.</p><p dir="RTL"><strong>إذا سهوت عن تناول أملوفار</strong></p><p dir="RTL">إذا سهوت عن تناول الكبسولات، فلا تقلق.<strong> </strong>تخطى الجرعة التي سهوت عنها وتناول الجرعة التالية في موعدها<strong> </strong>الصحيح. يجب عدم تناول جرعة مضاعفة لتعويض الجرعة التي قد سهوت عن تناولها.</p><p dir="RTL"><strong>إذا توقفت عن تناول أملوفار</strong></p><p dir="RTL">سوف يقدم لك طبيبك المعالج النصيحة حول المدة اللازمة لتناول هذا الدواء. من الممكن أن تعاود حالتك الصحية كما كانت إذا توقفت عن تناول هذا الدواء من تلقاء نفسك دون استشارة الطبيب المعالج.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي<strong> </strong>هذا الدواء، إلى حدوث تأثيرات جانبية، على الرغم من ذلك فإنها قد لا تحدث لكل شخص.</p><p dir="RTL">&nbsp;قم بزيارة الطبيب المعالج <strong>على الفور </strong>إذا عانيت<strong> </strong>من أية التأثيرات الجانبية التالية بعد تناول هذا الدواء:</p><p dir="RTL">&nbsp; أزيز مفاجئ، ألم&nbsp; في الصدر، ضيق أو صعوبة في التنفس.</p><p dir="RTL">&nbsp; تورم الجفون، الوجه أو الشفتين</p><p dir="RTL">&nbsp; تورم اللسان والحلق حيث يسبب صعوبة في التنفس.</p><p dir="RTL">&nbsp;&nbsp; تفاعلات جلدية شديدة بما في ذلك طفح جلدي حاد، طفح جلدي على شكل خلايا النحل، احمرار في الجلد بصورة منتشرة في جميع أنحاء الجسم، حكة شديدة، بثورجلدية، تقشر وتورم الجلد، التهاب الغشاء المخاطي (متلازمة ستيفن جونسون، انحلال البشرة السمي التنخري) أو تفاعلات تحسسية أخرى</p><p dir="RTL">&nbsp;&nbsp; أزمة قلبية، اضطرابات في ضربات القلب</p><p dir="RTL">&nbsp;&nbsp; التهاب البنكرياس من الممكن أن يسبب ألم شديد في البطن والظهر والذي يكون مصحوباً بالشعور بعدم الراحة</p><p dir="RTL">لقد تم تسجيل <strong>التأثيرات الشائعة جداً</strong> التالية. يجب عليك <strong>التواصل مع طبيبك المعالج</strong> إذا تسببت لك هذه التأثيرات في حدوث مشاكل أو إذا <strong>استمرت لمدة تزيد عن أسبوع واحد</strong>. يجب عليك <strong>التواصل مع طبيبك المعالج</strong>.</p><p dir="RTL"><strong>شائعة جداً: قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص</strong></p><p dir="RTL">&nbsp;&nbsp; وذمة) احتباس السوائل(</p><p dir="RTL">تم تسجيل <strong>التأثيرات الجانبية الشائعة التالية</strong>. يجب عليك <strong>التواصل مع الطبيب المعالج</strong> إذا تسببت لك هذه التأثيرات في حدوث مشاكل أو إذا استمرت <strong>لمدة تزيد عن أسبوع واحد</strong>.</p><p dir="RTL"><strong>شائعة: قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص</strong></p><p dir="RTL">&nbsp;&nbsp; صداع، دوخة، الشعور بالنعاس (بصفة خاصة في بداية فترة تلقي العلاج)</p><p dir="RTL">&nbsp;&nbsp; خفقان (الشعور بضربات القلب)، توهج</p><p dir="RTL">&nbsp;&nbsp; ألم في البطن، الشعور بالإعياء (غثيان)</p><p dir="RTL">&nbsp;&nbsp; اضطرابات في حركة الأمعاء، إسهال، إمساك، عسر هضم</p><p dir="RTL">&nbsp;&nbsp; الشعور بالتعب والضعف</p><p dir="RTL">&nbsp;&nbsp; اضطرابات في الرؤية، و ازدواج الرؤية</p><p dir="RTL">&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">&nbsp;&nbsp; تورم الكاحل</p><p dir="RTL">لقد تم تسجيل التأثيرات الجانبية الأخرى بما في ذلك القائمة التالية. يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه في حال زيادة حدة هذه التأثيرات الجانبية، أو إذا لاحظت حدوث أية تأثيرجانبي لم يذكر في هذه النشرة.</p><p dir="RTL"><strong>&nbsp;غير شائعة: قد تؤثرعلى ما يصل إلى شخص واحد من كل 100 شخص</strong></p><p dir="RTL">&nbsp;&nbsp; تقلبات مزاجية، قلق، اكتئاب وأرق</p><p dir="RTL">&nbsp;&nbsp; ارتعاش،اضطرابات في حاسة التذوق، إغماء</p><p dir="RTL">&nbsp;&nbsp; الشعور بالتخدر أو الوخز في الأطراف، فقد الإحساس بالألم</p><p dir="RTL">&nbsp;&nbsp; طنين في الأذنين</p><p dir="RTL">&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&nbsp;&nbsp; العطس/ سيلان الأنف الناجم عن الالتهاب في الغشاء المبطن للأنف (التهاب الأنف)</p><p dir="RTL">&nbsp;&nbsp; السعال</p><p dir="RTL">&nbsp;&nbsp; جفاف الفم، تقيؤ (شعور بالإعياء)</p><p dir="RTL">&nbsp;&nbsp; سقوط الشعر، زيادة التعرق، حكة وبقع حمراء على الجلد، تغير لون الجلد</p><p dir="RTL">&nbsp;&nbsp; اضطرابات في التبول، زيادة التبول الليلي، زيادة عدد مرات التبول</p><p dir="RTL">&nbsp;&nbsp; عدم القدرة على الإنتصاب، عدم الشعور بالراحة أو تضخم الثدي لدى الرجال</p><p dir="RTL">&nbsp;&nbsp; الشعور بالألم، الشعور بالإعياء</p><p dir="RTL">&nbsp;&nbsp; ألم في المفصل أوالعضل، ألم في الظهر</p><p dir="RTL">&nbsp;&nbsp; زيادة أو نقصان في الوزن</p><p dir="RTL"><strong>نادرة: قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL"><strong>نادرة جداً: قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص</strong></p><p dir="RTL"> نقص تعداد خلايا الدم البيضاء والصفائح الدموية التي قد تؤدي إلى حدوث كدمات غير معتادة أو حدوث النزيف بسهولة</p><p dir="RTL"> زيادة مستوى السكر في الدم (فرط سكر الدم)</p><p dir="RTL"> اضطرابات في الأعصاب حيث تؤدي إلى الشعور بضعف في العضلات، التنميل أو تخدر.</p><p dir="RTL"> تورم اللثة</p><p dir="RTL"> الشعور بالإمتلاء في البطن (التهاب المعدة)</p><p dir="RTL"> اضطرابات في وظائف الكبد، التهاب الكبد، اصفرار لون الجلد (يرقان)، زيادة انزيمات الكبد والتي تؤثر على بعض الفحوصات الطبية</p><p dir="RTL"> زيادة التوتر العضلي</p><p dir="RTL"> التهاب الأوعية الدموية، غالباً ما يكون مصحوباً بطفح جلدي</p><p dir="RTL"> الحساسية تجاه الضوء</p><p dir="RTL"> اضطرابات تجمع ما بين التصلب، ارتعاش، و/أو اضطرابات في الحركة</p><p dir="RTL"><strong>غير معروفة : لا يمكن تحديد معدل حدوثها من البيانات المتاحة</strong></p><p dir="RTL">&nbsp;&nbsp; ارتعاش، وضعية جسم متصلبة، قصور الإيماء، الحركة البطيئة، والمشي المتثاقل والغير متوازن.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات</strong><strong> </strong><strong>الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة.</strong></p><p dir="RTL"><strong>يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">-&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">-&nbsp;&nbsp; البريد الإلكترونيnpc.drug@sfda.gov.sa :</p><p dir="RTL">-&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL"><strong>&nbsp;&nbsp; </strong><strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong><strong>الرجاء الاتصال بجهات الوطنية في كل دولة.</strong></p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء. قسم اليقظة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم تناول <strong>أملوفار</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط.</p><p dir="RTL">-&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&deg;م، في مكان جاف</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم تناول <strong>أملوفار</strong> إذا لاحظت أي علامات تلف واضحة.</p><p dir="RTL">-&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp; ماهي محتويات أملوفار</strong></p><p dir="RTL">المادة الفعالة هي أملوديبين. تحتوي كل كبسولة على 5 ملغم من أملوديبين على هيئة أملوديبين بسيلات.</p><p dir="RTL">&nbsp;&nbsp; المواد غير الفعالة: بلورات سليلوز متناهية الصغر، فوسفات الكالسيوم ثنائي القاعدية، نشا جلايكولات الصوديوم، ثنائي أكسيد السيليكون &nbsp;الغروي، ستيرات المغنيسيوم، جيلاتين، لون الأصفر الكولينولين إي 104 وثنائي أكسيد التيتانيوم إي 171.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp; تتوفر كبسولات <strong>أملوفار</strong> في عبوات تحتوي على 30 كبسولة (شريطين يحتوي كلاً منهما على 15 كبسولة).</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot;جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            27/5/2021م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlophar 5mg Capsules. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains:
Item No.	Material Name	Scale (mg/Capsule)
		
	Active Ingredient:	
1.		Amlodipine Besylate	7.00
	Equivalent to Amlodipine	5.00
		
	Inactive Ingredients:	
1.		Microcrystalline cellulose (Avicel PH 102)	93.00
2.		Dibasic calcium phosphate	65.00
3.		Sodium starch glycolate (primojel)	8.00
4.		Colloidal silicon dioxide (Aerosil 200)	0.50
5.		Magnesium stearate	1.50
6.		Empty hard gelatine shell, size “3”*	1.00 nos.

*Composition of the capsule shell:
	Cap: Colour: yellow opaque
Composition: quinolone yellow E104, titanium dioxide E171.
	Body: Colour: white opaque
Composition: titanium dioxide E171.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard gelatin Capsules.
Description: Hard gelatin self-locking capsules, size “3” filled with off-white powder.
Marking:     Cap: Printed radical “Amlophar” in black.
                      Body: Printed “5” in black.
Colour:        Cap: Yellow opaque
                      Body: white opaque.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; Hypertension</p><p>&sect; Chronic stable angina pectoris</p><p>&sect; Vasospastic (Prinzmetal&#39;s) angina</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong>Adults</strong></p><p>For both hypertension and angina the usual initial dose is 5 mg amlodipine once daily which may be increased to a maximum dose of 10 mg depending on the individual patient&#39;s response.</p><p>In hypertensive patients, amlodipine has been used in combination with a thiazide diuretic, alpha blocker, beta blocker, or an angiotensin converting enzyme inhibitor. For angina, amlodipine may be used as monotherapy or in combination with other antianginal medicinal products in patients with angina that is refractory to nitrates and/or to adequate doses of beta blockers.</p><p>No dose adjustment of amlodipine is required upon concomitant administration of thiazide diuretics, beta blockers, and angiotensin-converting enzyme inhibitors.</p><p><strong><u>Special populations</u></strong></p><p><strong>Elderly patients</strong></p><p>Amlodipine used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care (see sections 4.4 and 5.2).</p><p><strong>Patients with hepatic impairment</strong></p><p>Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2). The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.</p><p><strong>Patients with renal impairment</strong></p><p>Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Amlodipine is not dialysable.</p><p><strong>Paediatric population</strong></p><p>&sect; <strong>Children and adolescents with hypertension from 6 years to 17 years of age.</strong></p><p>The recommended antihypertensive oral dose in paediatric patient&rsquo;s ages 6-17 years is 2.5mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in paediatric patients (see sections 5.1 and 5.2).</p><p>&sect; <strong>Children under 6 years old</strong></p><p>No data are available.</p><p><strong><u>Method of administration</u></strong></p><p>Capsules for oral administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlodipine is contraindicated in patients with:
	Hypersensitivity to dihydropyridine derivatives, amlodipine or to any of the excipients listed in section 6.1.
	Severe hypotension.
	Shock (including cardiogenic shock).
	Obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis).
	Haemodynamically unstable heart failure after acute myocardial infarction.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p><strong><u>Patients with cardiac failure</u></strong></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p><strong><u>Patients with hepatic impairment</u></strong></p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p><strong><u>Elderly patients</u></strong></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p><strong><u>Patients with renal impairment</u></strong></p><p>Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. amlodipine is not dialysable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effects of other medicinal products on amlodipine</u></strong></p><p><strong>CYP3A4 inhibitors</strong></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure resulting in an increased risk of hypotension. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p><strong>CYP3A4 inducers</strong></p><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum, perforatum).</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p><strong>Dantrolene (infusion)</strong></p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><strong><u>Effects of amlodipine on other medicinal products</u></strong></p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.</p><p><strong>Tacrolimus</strong></p><p>There is a risk of increased tacrolimus blood levels when co-administered with amlodipine but the pharmacokinetic mechanism of this interaction is not fully understood. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p><strong>Mechanistic Target of Rapamycin (mTOR) Inhibitors</strong></p><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.</p><p><strong>Cyclosporine</strong></p><p>No drug interaction studies have been conducted with cyclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of cyclosporine were observed. Consideration should be given for monitoring cyclosporine levels in renal transplant patients on amlodipine, and cyclosporine dose reductions should be made as necessary.</p><p><strong>Simvastatin</strong></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin or warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p>Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p><strong><u>Breast-feeding</u></strong></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3-7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.</p><p><strong><u>Fertility</u></strong></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile</u></strong></p><p>The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.</p><p><strong><u>Tabulated list of adverse reactions</u></strong></p><p>The following adverse reactions have been observed and reported during treatment with amlodipine with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:668px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukocytopenia,</p><p>thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Allergic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Depression, mood changes (including anxiety), insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Confusion</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:668px"><tbody><tr><td rowspan="4" style="vertical-align:top; width:237px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Somnolence, dizziness, headache (especially at the beginning of the treatment)</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Tremor, dysgeusia, syncope, hypoaesthesia, paraesthesia</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Very rare</p></td><td style="vertical-align:top; width:341px"><p>Hypertonia,</p><p>peripheral neuropathy</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Not Known</p></td><td style="vertical-align:top; width:341px"><p>Extrapyramidal disorder</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Eye disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Visual disturbance (including diplopia)</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Tinnitus</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:237px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Very rare</p></td><td style="vertical-align:top; width:341px"><p>Myocardial infarction</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:237px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Flushing</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Very rare</p></td><td style="vertical-align:top; width:341px"><p>Vasculitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:237px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Cough, rhinitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:237px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Abdominal pain, nausea, dyspepsia, altered bowel habits (including diarrhoea and constipation)</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Vomiting, dry mouth</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Very rare</p></td><td style="vertical-align:top; width:341px"><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:88px"><p>Very rare</p></td><td style="vertical-align:top; width:341px"><p>Hepatitis, jaundice, hepatic enzyme increased*</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:237px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, rash, exanthema, urticaria</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Very rare</p></td><td style="vertical-align:top; width:341px"><p>Angioedema, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Not known</p></td><td style="vertical-align:top; width:341px"><p>Toxic epidermal necrolysis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:237px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Ankle swelling, muscle cramps</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Arthralgia, myalgia, back pain</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Micturition disorder, nocturia, increased urinary frequency</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Impotence, gynaecomastia</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:237px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:88px"><p>Very common</p></td><td style="vertical-align:top; width:341px"><p>Oedema</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Common</p></td><td style="vertical-align:top; width:341px"><p>Fatigue, asthenia</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Chest pain, pain, malaise</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Investigations</p></td><td style="vertical-align:top; width:88px"><p>Uncommon</p></td><td style="vertical-align:top; width:341px"><p>Weight increased, weight decreased</p></td></tr></tbody></table><p>*mostly consistent with cholestasis</p><p><strong><u>To report any side effect(s): </u></strong></p><p>&sect; <strong>Saudi Arabia: </strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>- SFDA Call Centre: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other GCC States: </strong></p><p>- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In humans experience with intentional overdose is limited.</p><p><strong><u>Symptoms</u></strong></p><p>Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p><strong><u>Treatment</u></strong></p><p>Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Calcium channel blockers, selective calcium channel blockers with mainly vascular effects. ATC Code: C08CA01.</p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>1)&nbsp;&nbsp;&nbsp;&nbsp; Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</p><p>2)&nbsp;&nbsp;&nbsp;&nbsp; The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1 mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><strong><u>Use in patients with coronary artery disease (CAD)</u></strong></p><p>The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multi-centre, randomized, double-blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p><table border="1" cellspacing="0" cellpadding="0" style="width:675px"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 1. Incidence of significant clinical outcomes for CAMELOT</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><u>Cardiovascular event rates,</u></p><p><u>No. (%)</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Amlodipine vs. Placebo</u></p></td></tr><tr><td style="vertical-align:top"><p>Outcomes</p></td><td style="vertical-align:top"><p>Amlodipine</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Enalapril</p></td><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td style="vertical-align:top"><p><em>P</em>&nbsp;Value</p></td></tr><tr><td style="vertical-align:top"><p><u>Primary Endpoint</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Adverse cardiovascular events</p></td><td style="vertical-align:top"><p>110 (16.6)</p></td><td style="vertical-align:top"><p>151 (23.1)</p></td><td style="vertical-align:top"><p>136 (20.2)</p></td><td style="vertical-align:top"><p>0.69 (0.54-0.88)</p></td><td style="vertical-align:top"><p>.003</p></td></tr><tr><td style="vertical-align:top"><p><u>Individual Components</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Coronary revascularization</p></td><td style="vertical-align:top"><p>78 (11.8)</p></td><td style="vertical-align:top"><p>103 (15.7)</p></td><td style="vertical-align:top"><p>95 (14.1)</p></td><td style="vertical-align:top"><p>0.73 (0.54-0.98)</p></td><td style="vertical-align:top"><p>.03</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for angina</p></td><td style="vertical-align:top"><p>51 (7.7)</p></td><td style="vertical-align:top"><p>84 (12.8)</p></td><td style="vertical-align:top"><p>86 (12.8)</p></td><td style="vertical-align:top"><p>0.58 (0.41-0.82)</p></td><td style="vertical-align:top"><p>.002</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal MI</p></td><td style="vertical-align:top"><p>14 (2.1)</p></td><td style="vertical-align:top"><p>19 (2.9)</p></td><td style="vertical-align:top"><p>11 (1.6)</p></td><td style="vertical-align:top"><p>0.73 (0.37-1.46)</p></td><td style="vertical-align:top"><p>.37</p></td></tr><tr><td style="vertical-align:top"><p>Stroke or TIA</p></td><td style="vertical-align:top"><p>6 (0.9)</p></td><td style="vertical-align:top"><p>12 (1.8)</p></td><td style="vertical-align:top"><p>8 (1.2)</p></td><td style="vertical-align:top"><p>0.50 (0.19-1.32)</p></td><td style="vertical-align:top"><p>.15</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>2 (0.3)</p></td><td style="vertical-align:top"><p>5 (0.7)</p></td><td style="vertical-align:top"><p>2.46 (0.48-12.7)</p></td><td style="vertical-align:top"><p>.27</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for CHF</p></td><td style="vertical-align:top"><p>3 (0.5)</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>0.59 (0.14-2.47)</p></td><td style="vertical-align:top"><p>.46</p></td></tr><tr><td style="vertical-align:top"><p>Resuscitated cardiac arrest</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>.04</p></td></tr><tr><td style="vertical-align:top"><p>New-onset peripheral vascular disease</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>2 (0.3)</p></td><td style="vertical-align:top"><p>8 (1.2)</p></td><td style="vertical-align:top"><p>2.6 (0.50-13.4)</p></td><td style="vertical-align:top"><p>.24</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.</p></td></tr></tbody></table><p><strong><u>Use in patients with heart failure</u></strong></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>In a follow-up, long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema.</p><p><strong><u>Treatment to prevent heart attack trial (ALLHAT)</u></strong></p><p>A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p><strong><u>Use in children (aged 6 years and older)</u></strong></p><p>In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5 mg dose, and 5.0 mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.</p><p>The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood has also not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption, distribution, plasma protein binding:</u></strong><strong>&nbsp;</strong></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg.&nbsp;<em>In vitro&nbsp;</em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><strong><u>Biotransformation/elimination</u></strong></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><strong>Hepatic impairment</strong></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p><strong>Elderly population</strong></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p><strong>Paediatric population</strong></p><p>A population PK study has been conducted in 74 hypertensive children aged from 1 to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Reproductive toxicology</u></strong></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><strong><u>Impairment of fertility</u></strong></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m<sup>2</sup>&nbsp;basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p><strong><u>Carcinogenesis, mutagenesis</u></strong></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m<sup>2</sup>&nbsp;basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:653px"><tbody><tr><td style="vertical-align:top"><table border="0" cellspacing="0" cellpadding="0" style="width:645px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Microcrystalline cellulose (Avicel PH 102)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Dibasic calcium phosphate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium starch glycolate (primojel)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Colloidal silicon dioxide (Aerosil 200)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Magnesium stearate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Empty hard gelatin shell, size &ldquo;3&rdquo;*</li></ol></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>*<u>Composition of the capsule shell:</u></strong></p><p>&sect; <strong>Cap:</strong> Colour: yellow opaque</p><p>Composition: quinolone yellow E104, titanium dioxide E171.</p><p>&sect; <strong>Body:</strong> Colour: white opaque</p><p>Composition: titanium dioxide E171.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C, in a dry place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pack of 30 Capsules: </strong>15 capsules in a blister, 2 blisters packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street,
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                27. May. 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>